BIO-Europe Spring® 2016: Selexis CEO talks licensing, academic partnerships and biosimilars

May 10, 2016

Dr. Igor Fisch, CEO of Selexis SA, a drug discovery and cell-line development services company, speaks to Mike Ward, global director of content for Informa Pharma Intelligence's insights portfolio, about Selexis' focus on biologics and its business model centered on licensing deals. During BIO-Europe Spring 2016 in Stockholm, Sweden, the pair discuss Selexis' unique selling point, how the company works with academia to produce innovative technology, and how the growing biosimilars market might affect the business in coming years.

 


Want to elevate your brand and connect with potential partners? The Cell & Gene Exchange brings together leaders from patient advocacy groups, industry, academia and government to network, exchange ideas and explore partnership opportunities. Learn more here. 

Previous Video
BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech
BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech

Dr. Graham Lumsden, CEO of London-based biotech Motif Bio, a company focused on the development of therapeu...

Next Video
BIO-Europe Spring® 2016: CEVEC CEO talks US deals to expand business
BIO-Europe Spring® 2016: CEVEC CEO talks US deals to expand business

Frank Ubags, CEO of CEVEC—a company offering industrial scale production of viral vectors for gene therapy ...